Pancreatic Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

PNCA MCID: PNC035 MIFTS: 91	Pancreatic Cancer (PNCA) Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Pancreatic Cancer

MalaCards integrated aliases for Pancreatic Cancer:

Name: Pancreatic Cancer ⁵⁷ ¹¹ ¹⁹ ⁷⁵ ⁷³ ¹² ⁵³ ⁴¹ ¹⁴ ³⁶ ³³

Pancreatic Carcinoma ⁵⁷ ¹¹ ⁷³ ⁵³ ⁴³ ¹⁴ ¹⁶ ⁷¹ ³³

Familial Pancreatic Carcinoma ¹⁹ ⁵⁸ ²⁸ ⁵

Pancreatic Carcinoma, Familial ¹¹ ⁷⁵ ⁷¹

Malignant Neoplasm of Pancreas ⁷¹ ³¹ ³³

Carcinoma of Pancreas ¹¹ ²⁸ ⁵

Pancreatic Neoplasm ¹¹ ¹⁶ ⁷¹

Pancreatic Acinar Carcinoma ⁵⁷ ⁷³

Familial Pancreatic Cancer ¹⁹ ⁵⁸

Neoplasm of the Pancreas ²⁸ ⁵

Pancreatic Tumor ¹¹ ⁵³

Mixed Islet Cell with Exocrine Carcinoma of Unspecified Site ³³

Malignant Neoplasm of Body of Pancreas ¹¹

Malignant Neoplasm of Head of Pancreas ¹¹

Malignant Neoplasm of Tail of Pancreas ¹¹

Pancreatic Cancer, Susceptibility to ⁵

Hereditary Pancreatic Carcinoma ¹⁹

Pancreatic Carcinoma, Somatic ⁵⁷

Carcinoma of Head of Pancreas ⁵

Hereditary Pancreatic Cancer ¹⁹

Exocrine Pancreas Carcinoma ¹¹

Pancreatic Cancer, Somatic ⁵⁷

Cancer of the Pancreas ⁵

Pancreatic Neoplasms ⁴³

Ca Body of Pancreas ¹¹

Ca Head of Pancreas ¹¹

Ca Tail of Pancreas ¹¹

Cancer, Pancreatic ³⁸

Cancer of Pancreas ³³

Pancreas Neoplasm ¹¹

Pancreatic Tumors ¹⁴

Exocrine Cancer ¹¹

Pnca ⁷³

Characteristics:

Inheritance:

Pancreatic Cancer: Autosomal dominant ⁵⁷

Familial Pancreatic Carcinoma: Autosomal dominant,Multigenic/multifactorial ⁵⁸

Age Of Onset:

Familial Pancreatic Carcinoma: Adult ⁵⁸

OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Miscellaneous:
may be seen with other forms of cancer in a family

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Gastrointestinal diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of pancreas

Malignant neoplasm: Body of pancreas

Malignant neoplasm: Head of pancreas

Malignant neoplasm: Pancreas, unspecified

Malignant neoplasm: Tail of pancreas

ICD11: ³³

Neoplasms

Malignant neoplasms, except primary neoplasms of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic, central nervous system or related tissues

Malignant neoplasms of digestive organs

Malignant neoplasm of pancreas

Malignant neoplasm of pancreas, unspecified

Other specified malignant neoplasms of pancreas

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹¹ DOID:1793 DOID:4905

OMIM® ⁵⁷ 260350

ICD9CM ³⁴ 157.0 157.1 157.2 more

MeSH ⁴³ C562463 D010190

NCIt ⁴⁹ C3305 C3850

SNOMED-CT ⁶⁸ 126859007 154475002 187796007 more

ICD10 ³¹ C25 C25.0 C25.1 more

MESH via Orphanet ⁴⁴ C535837

ICD10 via Orphanet ³² C25

UMLS via Orphanet ⁷² C2931038

Orphanet ⁵⁸ ORPHA1333

MedGen ⁴⁰ C0235974

EFO ¹⁶ EFO_0002618 EFO_0003860

ICD11 ³³ 542147910 542147910/other 542147910/unspecified

UMLS ⁷¹ C0030297 C0153458 C0153459 more

Sources

Summaries for Pancreatic Cancer

MedlinePlus: ⁴¹ The pancreas is a gland behind your stomach and in front of your spine. It produces the juices that help break down food and the hormones that help control blood sugar levels. Pancreatic cancer usually begins in the cells that produce the juices. Some risk factors for developing pancreatic cancer include: Smoking Long-term diabetes Chronic pancreatitis Certain hereditary disorders Pancreatic cancer is hard to catch early. It doesn't cause symptoms right away. When you do get symptoms, they are often vague or you may not notice them. They include yellowing of the skin and eyes, pain in the abdomen and back, weight loss and fatigue. Also, because the pancreas is hidden behind other organs, health care providers cannot see or feel the tumors during routine exams. Doctors use a physical exam, blood tests, imaging tests, and a biopsy to diagnose it. Because it is often found late and it spreads quickly, pancreatic cancer can be hard to treat. Possible treatments include surgery, radiation, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary: Pancreatic Cancer, also known as pancreatic carcinoma, is related to breast cancer and pancreatic ductal adenocarcinoma, and has symptoms including nausea and vomiting, constipation and abdominal pain. An important gene associated with Pancreatic Cancer is SMAD4 (SMAD Family Member 4), and among its related pathways/superpathways are Gene expression (Transcription) and ERK Signaling. The drugs Thrombin and Levodopa have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, exocrine pancreas and t cells, and related phenotypes are pancreatic adenocarcinoma and exocrine pancreatic insufficiency

GARD: ¹⁹ Familial pancreatic cancer (FPC) is the occurrence of pancreatic cancer in two or more first-degree relatives (parent and child, or two siblings). It is sometimes referred to as FPC only when there is not a known hereditary cancer syndrome in an affected family. In 60% of cases it occurs within the head of the pancreas. Symptoms of pancreatic cancer are generally non-specific and may include pain in the upper abdomen that radiates to the back; loss of appetite; significant weight loss; and jaundice due to bile duct obstruction. Pancreatic cancer often goes undetected until the advanced stages of the disease, and rapid tumor growth and metastasis are common. A specific genetic cause of FPC (in the absence of a known syndrome) has not been identified. Familial cases of pancreatic cancer due to hereditary conditions may be caused by genetic changes in any of several genes. Individuals who carry a genetic change in one of these genes are often at an increased risk of other types of cancers as well. In many cases, inheritance of a predisposition to develop FPC is autosomal dominant. In some cases, is may be multifactorial.

OMIM®: ⁵⁷ Pancreatic cancer shows among the highest mortality rates of any cancer, with a 5-year relative survival rate of less than 5%. By the time of initial diagnosis, metastatic disease is commonly present. Established risk factors include a family history of pancreatic cancer, a medical history of diabetes type 2, and cigarette smoking (summary by Amundadottir et al., 2009). (260350) (Updated 08-Dec-2022)

UniProtKB/Swiss-Prot: ⁷³ A malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue.

Disease Ontology ¹¹ Pancreatic cancer: An endocrine gland cancer located in the pancreas.

Pancreatic carcinoma: A pancreas cancer that derives from epithelial cells located in the exocrine pancreas.

Orphanet: ⁵⁸ Familial pancreatic carcinoma is defined by the presence of pancreatic cancer (PC) in two or more first-degree relatives.

Wikipedia: ⁷⁵ Pancreatic cancer arises when cells in the pancreas, a glandular organ behind the stomach, begin to... more...

Sources

Related Diseases for Pancreatic Cancer

Diseases in the Pancreatic Cancer family:

Pancreatic Cancer 1	Pancreatic Cancer 2
Pancreatic Cancer 3	Pancreatic Cancer 4
Pancreatic Cancer 5

Diseases related to Pancreatic Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1502)

#	Related Disease	Score	Top Affiliating Genes
1	breast cancer	34.0	TSC1 TP53 STK11 SMAD4 RBBP8 PALB2
2	pancreatic ductal adenocarcinoma	33.8	TP53 SMAD4 MIR221 MIR21 MIR17 MIR155
3	dysplastic nevus syndrome	33.7	STK11 PALB2 BRCA2 BRCA1 ATM
4	melanoma, cutaneous malignant 1	33.3	TP53 STK11 PALB2 MIR17 CHEK2 BRCA2
5	pancreatic adenocarcinoma	33.3	TP53 SMAD4 KRAS BRCA2
6	adenocarcinoma	33.2	TP53 STK11 SMAD4 KRAS C11orf65 BRCA2
7	cystadenocarcinoma	33.1	TP53 MIR21 KRAS BRCA2 BRCA1
8	colorectal cancer	33.0	TP53 STK11 SMAD4 PALB2 NBN MIR221
9	pancreatic signet ring cell adenocarcinoma	33.0	TP53 PALB2 KRAS
10	ovarian cancer	32.9	TP53 SMAD4 RBBP8 PALB2 NBN MIR221
11	hereditary breast ovarian cancer syndrome	32.9	TP53 STK11 SMAD4 RBBP8 PALB2 NBN
12	malignant exocrine pancreas neoplasm	32.9	TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
13	bap1 tumor predisposition syndrome	32.9	TSC1 TP53 STK11 SMAD4 PALB2 NBN
14	inherited cancer-predisposing syndrome	32.9	TSC1 TP53 STK11 SMAD4 PALB2 NBN
15	lynch syndrome	32.8	TP53 STK11 SMAD4 PALB2 MIR17 KRAS
16	lung cancer	32.8	TP53 STK11 SMAD4 PALB2 NBN MIR221
17	gastric cancer	32.6	TP53 STK11 SMAD4 MIR221 MIR21 MIR17
18	cholangiocarcinoma	32.5	TP53 SMAD4 MIR21 KRAS BRCA2 BRCA1
19	type 2 diabetes mellitus	32.5	TSC1 TP53 STK11 MIR221 MIR21 MIR17
20	ataxia-telangiectasia	32.4	TP53 STK11 RBBP8 NBN CHEK2 C11orf65
21	deficiency anemia	32.4	TP53 SMAD4 PALB2 BRIP1 BRCA2 BRCA1
22	colonic benign neoplasm	32.3	TP53 SMAD4 PALB2 MIR21 KRAS CHEK2
23	esophageal cancer	32.3	TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
24	peripheral nervous system disease	32.2	TP53 MIR21 MIR17 KRAS BRCA1 ATM
25	body mass index quantitative trait locus 11	32.2	TP53 MIR221 MIR21 MIR17 MIR155 MIR10A
26	peutz-jeghers syndrome	32.2	TSC1 TP53 STK11 SMAD4 BRCA2
27	prostate cancer	32.2	TP53 SMAD4 NBN MIR221 MIR21 MIR17
28	fanconi anemia, complementation group a	32.2	TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
29	pancreatic ductal carcinoma	32.2	TP53 SMAD4 KRAS
30	li-fraumeni syndrome	32.2	TP53 STK11 SMAD4 PALB2 KRAS CHEK2
31	bile duct cancer	32.1	TP53 SMAD4 MIR221 MIR21 MIR17 KRAS
32	telangiectasis	32.1	TP53 SMAD4 NBN CHEK2 ATM
33	glioblastoma	32.1	TP53 MIR221 MIR21 MIR155 KRAS C11orf65
34	wilms tumor 1	32.0	TP53 PALB2 KRAS CHEK2 BRCA2 BRCA1
35	lung cancer susceptibility 3	32.0	TP53 STK11 SMAD4 MIR21 MIR17 KRAS
36	aplastic anemia	31.9	TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
37	biliary tract cancer	31.9	TP53 SMAD4 MIR221 MIR21 MIR17
38	ovarian cancer 1	31.9	PALB2 NBN BRIP1 BRCA2 BRCA1
39	lynch syndrome 1	31.9	PALB2 CHEK2 ATM
40	renal cell carcinoma, nonpapillary	31.8	TSC1 TP53 MIR221 MIR21 MIR17 MIR155
41	endometrial cancer	31.8	TP53 SMAD4 MIR21 KRAS BRCA2 BRCA1
42	bladder cancer	31.8	TSC1 TP53 MIR221 MIR21 MIR17 MIR10A
43	breast ductal carcinoma	31.8	TP53 SMAD4 BRCA2 BRCA1
44	appendix adenocarcinoma	31.8	TP53 SMAD4 KRAS
45	breast-ovarian cancer, familial 1	31.8	PALB2 NBN BRIP1 BRCA2 BRCA1
46	leukemia, acute myeloid	31.8	TP53 MIR221 MIR21 MIR17 MIR155 MIR10A
47	rectum cancer	31.8	TP53 MIR221 MIR21 MIR17 KRAS
48	papillary adenocarcinoma	31.8	TP53 MIR221 MIR21 KRAS BRCA1
49	hereditary breast cancer	31.7	PALB2 CHEK2 BRCA2 BRCA1
50	cowden syndrome 1	31.7	TSC1 TP53 STK11 SMAD4 PALB2 CHEK2

Comorbidity relations with Pancreatic Cancer via Phenotypic Disease Network (PDN): (show all 11)

Active Peptic Ulcer Disease	Acute Cystitis
Acute Pancreatitis	Cholangitis
Cholestasis	Deficiency Anemia
Intestinal Obstruction	Pancreatic Agenesis 1
Pancreatitis, Hereditary	Protein-Energy Malnutrition
Somatostatinoma

Graphical network of the top 20 diseases related to Pancreatic Cancer:

Sources

Symptoms & Phenotypes for Pancreatic Cancer

Human phenotypes related to Pancreatic Cancer:

⁵⁸ ³⁰ (show all 26)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	pancreatic adenocarcinoma ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0006725
2	exocrine pancreatic insufficiency ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001738
3	back pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0003418
4	abdominal pain ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002027
5	anorexia ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0002039
6	chronic fatigue ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0012432
7	weight loss ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001824
8	poor appetite ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0004396
9	jaundice ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0000952
10	lymphadenopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002716
11	intestinal pseudo-obstruction ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0004389
12	extrahepatic cholestasis ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012334
13	functional intestinal obstruction ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0005249
14	nausea and vomiting ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002017
15	diabetes mellitus ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000819
16	elevated hepatic transaminase ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002910
17	melanoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002861
18	breast carcinoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003002
19	neoplasm of the liver ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002896
20	colon cancer ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003003
21	intermittent diarrhea ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002254
22	hepatosplenomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001433
23	ovarian carcinoma ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0025318
24	peritoneal abscess ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100592
25	neoplasm of the pancreas ³⁰			HP:0002894
26	increased level of l-fucose in urine ³⁰			HP:0410067

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Abdomen Pancreas:
pancreatic cancer
pancreatic ductal adenocarcinoma

Neoplasia:
pancreatic ductal adenocarcinoma

Clinical features from OMIM®:

260350 (Updated 08-Dec-2022)

UMLS symptoms related to Pancreatic Cancer:

nausea and vomiting; constipation; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 22)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	10.39	KRAS
2	Decreased viability	GR00055-A-2	10.39	KRAS
3	Decreased viability	GR00055-A-3	10.39	KRAS
4	Decreased viability	GR00106-A-0	10.39	KRAS
5	Decreased viability	GR00221-A-1	10.39	ACVR1B KRAS
6	Decreased viability	GR00221-A-2	10.39	ACVR1B BRCA1 CHEK2 KRAS TSC1
7	Decreased viability	GR00221-A-3	10.39	BRCA1 CHEK2 TSC1
8	Decreased viability	GR00221-A-4	10.39	ACVR1B CHEK2
9	Decreased viability	GR00301-A	10.39	BRCA1 KRAS TSC1
10	Decreased viability	GR00342-S-2	10.39	CHEK2
11	Decreased viability	GR00381-A-1	10.39	KRAS
12	Decreased homologous recombination repair frequency	GR00151-A-1	10.06	BRCA1 RBBP8
13	Decreased homologous recombination repair frequency	GR00151-A-2	10.06	BRCA1 RBBP8
14	Decreased homologous recombination repair frequency	GR00236-A-1	10.06	BRCA1 BRCA2 PALB2 RBBP8
15	Decreased homologous recombination repair frequency	GR00236-A-2	10.06	BRCA1 BRCA2 PALB2 RBBP8
16	Decreased homologous recombination repair frequency	GR00236-A-3	10.06	BRCA1 BRCA2 PALB2 RBBP8
17	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	10.05	BRCA1 BRCA2 NBN PALB2 STK11
18	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	10.05	ATM BRCA1 BRCA2 BRIP1 PALB2 STK11
19	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	10.05	ATM BRCA1 BRCA2 CHEK2 NBN TP53
20	Synthetic lethal with cisplatin	GR00101-A-1	9.5	BRCA1 BRCA2 BRIP1
21	Decreased viability with cisplatin	GR00101-A-4	9.43	BRCA1 BRCA2 BRIP1
22	Decreased viability after ionizing radiation	GR00232-A-2	9.13	ATM BRCA1 BRCA2

MGI Mouse Phenotypes related to Pancreatic Cancer:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	neoplasm	MP:0002006	10.34	ATM BRCA1 BRCA2 BRIP1 CHEK2 KRAS
2	nervous system	MP:0003631	10.27	ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
3	endocrine/exocrine gland	MP:0005379	10.21	ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
4	cellular	MP:0005384	10.2	ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
5	embryo	MP:0005380	10.18	ACVR1B ATM BRCA1 BRCA2 KRAS NBN
6	normal	MP:0002873	10.13	ACVR1B BRCA1 BRCA2 KRAS MIR10A MIR155
7	immune system	MP:0005387	10.03	ACVR1B ATM BRCA1 BRCA2 CHEK2 KRAS
8	digestive/alimentary	MP:0005381	9.97	ACVR1B BRCA1 BRCA2 KRAS MIR155 SMAD4
9	reproductive system	MP:0005389	9.93	ACVR1B ATM BRCA1 BRCA2 BRIP1 CHEK2
10	mortality/aging	MP:0010768	9.8	ACVR1B ATM BRCA1 BRCA2 CHEK2 KRAS
11	integument	MP:0010771	9.32	ACVR1B ATM BRCA1 BRCA2 KRAS PALB2

Sources

Drugs & Therapeutics for Pancreatic Cancer

Drugs for Pancreatic Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 694)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Thrombin

Approved, Investigational

Phase 4

Levodopa

Approved

Phase 4

59-92-7, 63-84-3

6047

Midazolam

Approved, Illicit

Phase 4

59467-70-8

4192

Sevoflurane

Approved, Vet_approved

Phase 4

28523-86-6

5206

Rocuronium

Approved

Phase 4

119302-91-9, 143558-00-3

441290

Desflurane

Approved

Phase 4

57041-67-5

42113

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Bupropion

Approved

Phase 4

31677-93-7, 34841-39-9, 34911-55-2

444

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Nicotine

Approved

Phase 4

54-11-5

942 89594

Etomidate

Approved

Phase 4

33125-97-2

667484

Meperidine

Approved

Phase 4

57-42-1

4058

Dexmedetomidine

Approved, Experimental, Vet_approved

Phase 4

86347-14-0, 113775-47-6

68602 5311068

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Sufentanil

Approved, Investigational

Phase 4

56030-54-7

41693

Lutetium Lu 177 dotatate

Approved, Investigational

Phase 4

437608-50-9

76966897

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Pasireotide

Approved

Phase 4

396091-73-9

56841596 9941444

Oxaliplatin

Approved, Investigational

Phase 4

61825-94-3

43805 11947679 6857599

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

3003 5743

Dronabinol

Approved, Illicit

Phase 4

1972-08-3

16078

Pregabalin

Approved, Investigational

Phase 4

148553-50-8

5486971

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Mirtazapine

Approved

Phase 4

85650-52-8, 61337-67-5

4205

Tramadol

Approved, Investigational

Phase 4

27203-92-5

33741 5523

Oxycodone

Approved, Illicit, Investigational

Phase 4

76-42-6

5284603

L-Glutamine

Approved, Investigational, Nutraceutical

Phase 4

56-85-9

5961

Arginine

Approved, Investigational, Nutraceutical

Phase 4

74-79-3

6322

Lysine

Approved, Nutraceutical

Phase 4

56-87-1

5962

Nimotuzumab

Investigational

Phase 4

780758-10-3

Polygeline

Experimental

Phase 4

66455-30-9

Soy Bean

Phase 4

Parenteral Nutrition Solutions

Phase 4

Coagulants

Phase 4

Blood Substitutes

Phase 4

Plasma Substitutes

Phase 4

Fibrin Tissue Adhesive

Phase 4

Dihydroxyphenylalanine

Phase 4

Fat Emulsions, Intravenous

Phase 4

Soybean oil, phospholipid emulsion

Phase 4

Anesthetics, General

Phase 4

Omega 3 Fatty Acid

Phase 4

Central Nervous System Stimulants

Phase 4

Interventional clinical trials:

(show top 50) (show all 2946)

#	Name	Status	NCT ID	Phase	Drugs
1	The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer	Unknown status	NCT03401827	Phase 4	Chemotherapy (Gemcitabine + nab-paclitaxel)
2	A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment	Unknown status	NCT02945267	Phase 4	Nimotuzumab plus S1;Placebo plus S1
3	Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial	Unknown status	NCT01642875	Phase 4
4	H.O.P.E. Healing Optimization Through Preoperative Engagement: A Prospective Single Cohort Study to Evaluate the Effect of a Prehabilitation Program on Preoperative Outcomes in Upper GI Surgical Oncology Patients	Unknown status	NCT03642093	Phase 4
5	Glycocalyx Levels in Patients Undergoing Pancreatectomy With Human Albumin 5% vs. Gelofusine	Unknown status	NCT04058236	Phase 4
6	Prospective, Randomized, Open-label, Controlled Trial of Cyclooxygenase-2 Inhibitor (Celecoxib; Celebrex®) for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer.	Unknown status	NCT01111591	Phase 4	Cox2 inhibitor (Celecoxib)
7	The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy	Unknown status	NCT03269955	Phase 4	Fibrinogen/thrombin-coated collagen patch
8	Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy	Unknown status	NCT01969110	Phase 4
9	Randomized Controlled Study to Evaluate the Effect of Thrombin-containing Collagen-based Hemostatic Matrix on Prevention of Pancreatic Fistula After Pancreatecomy	Unknown status	NCT04357483	Phase 4	flowable thrombin containing collagen hemostat matrix;thrombin coated L-dopa contained collagen patch
10	Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms	Unknown status	NCT01673334	Phase 4
11	Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery	Unknown status	NCT01819961	Phase 4	MCT/LCT and fish oil;MCT/LCT
12	Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients With the Aim of Reducing Toxicity	Unknown status	NCT04269369	Phase 4	5-Fluorouracil
13	Randomized Clinical Trial of Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Undergoing Chemotherapy Treatment.	Completed	NCT00966277	Phase 4	Dalteparin
14	A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients	Completed	NCT02812992	Phase 4	Nab-paclitaxel;Gemcitabine
15	Improved Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI)	Completed	NCT00920023	Phase 4	Superparamagnetic Iron Oxide Magnetic Resonance Imaging
16	Enhancing Tobacco Use Treatment for African American Light Smokers	Completed	NCT00666978	Phase 4	bupropion hydrochloride
17	Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP)	Completed	NCT02027311	Phase 4	Etomidate;Midazolam;Meperidine
18	Title: The Impact of Immunostimulating Nutrition on Infectious Complications After Upper Gastrointestinal Surgery - A Prospective, Randomized, Clinical Trial.	Completed	NCT00558155	Phase 4	peptisorb;Stresson;Parenteral nutrition;Omegaven, Dipeptiven
19	A Prospective Study of Celiac Block Technique: One Injection or Two?	Completed	NCT00583479	Phase 4
20	Standard and Immunostimulating Enteral Nutrition in Patients After Extended Gastrointestinal Surgery - A Prospective, Randomized, Controlled Clinical Trial	Completed	NCT00576940	Phase 4	Reconvan;Peptisorb
21	Covered Versus Uncovered Metal Stents for Management of Distal Malignant Biliary Obstruction? Results of a Randomized Prospective Study.	Completed	NCT00280709	Phase 4
22	Comparing the Lozenge to the Patch for Smoking Cessation	Completed	NCT00365508	Phase 4	nicotine lozenge;nicotine patch
23	Prospective Randomized Trial Comparing Covered Metal Stents Placed Above and Across the Sphincter of Oddi in Malignant Biliary Obstruction: A Multi-nation, Multi-center Study	Completed	NCT01041612	Phase 4
24	Endoscopic Ultrasound-guided Celiac Plexus Neurolysis (EUS-CPN) With Alcohol in Patients With Locally Advanced and Unresectable Pancreatic Adenocarcinoma: A Randomized Pilot Study	Completed	NCT00578279	Phase 4	dehydrated alcohol
25	Effects of Preoperative Immunonutrition on Infectious Complication and Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy	Completed	NCT01256034	Phase 4
26	A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses	Completed	NCT02092519	Phase 4
27	The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study	Completed	NCT02728921	Phase 4	5% Albumin infusion 30 min;5% Albumin infusion 3 hours
28	RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction	Completed	NCT00980889	Phase 4
29	Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?	Completed	NCT02335151	Phase 4	Desflurane
30	Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours	Completed	NCT02044224	Phase 4	Dexmedetomidine
31	Effect of Perioperative Epidural Block and Dexamethasone on Outcome of Patients Undergoing Pancreatic Cancer Surgery: a 2×2 Factorial Randomized Controlled Trial	Recruiting	NCT04025840	Phase 4	Dexamethasone
32	Non-inferiority Study of Albumin-bound Paclitaxel Combined With Gemcitabine for Three Weeks Versus Four Weeks for First-line Inoperable Locally Advanced or Metastatic Pancreatic Cancer	Recruiting	NCT05035147	Phase 4	albumin-bound paclitaxel
33	Endoscopic Ultrasound Guided Coeliac Plexus Block Versus Radiofrequency Ablation in Pain Relief of Patients With Intractable Pain Due to Malignancy A Randomized Controlled Study	Recruiting	NCT04809935	Phase 4	98% dehydrated alcohol
34	Pre- vs. Postoperative Thromboprophylaxis in Pancreatic Surgery - a Prospective, Multicenter, Randomized Controlled Trial (PREPOSTEROUS Pancreas Trial)	Recruiting	NCT05245877	Phase 4	enoxaparin/tinzaparin/dalteparin
35	A Multicenter, Open-label Post Authorization Safety Study to Evaluate the Effect of LysaKare® Infusion on Serum Potassium Levels in GEP-NET Patients Eligible for Lutathera® Treatment	Recruiting	NCT04524442	Phase 4	arginine/lysine
36	HYPAR Trial - Hydrocortisone vs Pasireotide in Reducing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial	Active, not recruiting	NCT02775227	Phase 4	Hydrocortisone;Pasireotide
37	A Single-arm, Prospective Study to Evaluate the Efficacy and Safety of the Combination of Paclitaxel Liposome and S-1 as First-line Therapy in Treating Patients With Advanced Metastatic Pancreatic Cancer	Not yet recruiting	NCT04217096	Phase 4	Paclitaxel liposome;S-1
38	A Window-of-Opportunity Trial Using Neoadjuvant Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer	Not yet recruiting	NCT05634720	Phase 4	HA Chemotherapy
39	Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects	Terminated	NCT03859869	Phase 4	Pancrelipase;Placebo
40	Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice	Terminated	NCT01887041	Phase 4
41	An Open Label Study to Evaluate the Effect of First Line Treatment With Tarceva in Combination With Gemcitabine on Overall Survival and Disease Progression in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer	Terminated	NCT00642733	Phase 4	erlotinib [Tarceva];gemcitabine
42	Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study	Terminated	NCT01768988	Phase 4	Placebo;Pregabalin
43	Assessing Quality of Life and the Feasibility of a Nutrition and Pharmacological Algorithm for Oncology Patients With Anorexia	Terminated	NCT04155008	Phase 4	Dexamethasone;Dronabinol;Mirtazapine
44	A Phase 4 Open-Label Single-Arm Study To Evaluate The Use Of CREON In Subjects With EPI Due To Etiologies Other Than Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer	Withdrawn	NCT04315311	Phase 4	CREON
45	Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy	Withdrawn	NCT02570529	Phase 4	Albis®;Placebo
46	Exocrine Pancreatic Insufficiency in Pancreatic Cancer: Evaluating the Need and Efficacy of Pancreatic Enzyme Replacement Therapy	Withdrawn	NCT01401387	Phase 4
47	A Pilot Study of Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma	Withdrawn	NCT03891979	Phase 4	Pembrolizumab;Ciprofloxacin 500mg PO BID days 1-29;Metronidazole 500mg PO TID days 1-29
48	A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection	Unknown status	NCT02506842	Phase 3	nab-paclitaxel;gemcitabine;oxaliplatin;folinic acid;fluorouracil
49	Phase II Study: Neoadjuvant Gemcitabine, Docetaxel and Capecitabine Followed by Neoadjuvant Radiation Therapy With Gemcitabine and Capecitabine in the Treatment of Stage II and III Pancreatic Adenocarcinoma	Unknown status	NCT01065870	Phase 2, Phase 3	Neoadjuvant gemcitabine, capecitabine, and docetaxel;Gemcitabine, capecitabine, docetaxel followed by radiotherapy
50	Gemcitabine vs Gemcitabine + Cisplatin in the Treatment of Advanced Pancreatic Cancer (Stage II III IV)	Unknown status	NCT00813696	Phase 3	gemcitabine;cisplatin

Search NIH Clinical Center for Pancreatic Cancer

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

docetaxel

Fluorouracil

Ifosfamide

irinotecan

Irinotecan hydrochloride

Octreotide

Octreotide Acetate

sunitinib

sunitinib malate

Tamoxifen

Tamoxifen Citrate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Pancreatic Cancer cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Pancreatic Cancer:

Tumor infiltrating lymphocytes (TILs) for solid tumors

Embryonic/Adult Cultured Cells Related to Pancreatic Cancer:

Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: pancreatic neoplasms

Sources

Genetic Tests for Pancreatic Cancer

Genetic tests related to Pancreatic Cancer:

#	Genetic test	Affiliating Genes
1	Carcinoma of Pancreas ²⁸	KRAS SMAD4 STK11 TP53
2	Neoplasm of the Pancreas ²⁸
3	Familial Pancreatic Carcinoma ²⁸

Sources

Anatomical Context for Pancreatic Cancer

Organs/tissues related to Pancreatic Cancer:

FMA: Pancreas, Exocrine Pancreas

MalaCards : Pancreas, T Cells, Lymph Node, Liver, Breast, Colon, Lung

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Cancer:

#	Tissue Anatomical CompartmentCell	Relevance
1	Pancreas Pancreatic Acini Acinar Cells

Sources

Publications for Pancreatic Cancer

Articles related to Pancreatic Cancer:

(show top 50) (show all 45617)

#	Title	Authors	PMID	Year
1	Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. ⁵³ ⁵⁷ ⁵	Al-Sukhni W...Gallinger S	18762988	2008
2	ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. ⁵³ ⁶² ⁵	Su GH...Kern SE	11248065	2001
3	DPC4 gene in various tumor types. ⁵³ ⁶² ⁵	Schutte M...Kern SE	8653691	1996
4	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. ⁵³ ⁶² ⁵⁷	Caldas C...Kern SE	7726912	1994
5	p53 mutations are common in pancreatic cancer and are absent in chronic pancreatitis. ⁵³ ⁶² ⁵	Casey G...Korc M	8513440	1993
6	A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. ⁶² ⁵⁷	Jermusyk A...Amundadottir LT	34559995	2021
7	Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. ⁶² ⁵⁷	Yamamoto K...Kimmelman AC	32376951	2020
8	Cysteine depletion induces pancreatic tumor ferroptosis in mice. ⁶² ⁵⁷	Badgley MA...Olive KP	32241947	2020
9	The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. ⁶² ⁵⁷	Engle DD...Tuveson DA	31221853	2019
10	Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. ⁶² ⁵⁷	Shi Y...Hunter T	30996350	2019
11	Syndecan 1 is a critical mediator of macropinocytosis in pancreatic cancer. ⁶² ⁵⁷	Yao W...Draetta GF	30918400	2019
12	Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. ⁶² ⁵⁷	Dey P...DePinho RA	28099419	2017
13	A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. ⁶² ⁵⁷	Notta F...Gallinger S	27732578	2016
14	Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation. ⁶² ⁵⁷	Zheng J...Lin D	27213290	2016
15	Genomic analyses identify molecular subtypes of pancreatic cancer. ⁶² ⁵⁷	Bailey P...Grimmond SM	26909576	2016
16	Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism. ⁶² ⁵⁷	Perera RM...Bardeesy N	26168401	2015
17	Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. ⁶² ⁵⁷	Melo SA...Kalluri R	26106858	2015
18	BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. ⁶² ⁵⁷	Zhen DB...Petersen GM	25356972	2015
19	Whole genomes redefine the mutational landscape of pancreatic cancer. ⁶² ⁵⁷	Waddell N...Grimmond SM	25719666	2015
20	Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. ⁶² ⁵⁷	Son J...Kimmelman AC	23535601	2013
21	Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. ⁶² ⁵⁷	Biankin AV...Grimmond SM	23103869	2012
22	CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. ⁶² ⁵⁷	Ghiorzo P...Genoa Pancreatic Cancer Study Group	22368299	2012
23	CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. ⁶² ⁵⁷	Beatty GL...Vonderheide RH	21436454	2011
24	mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. ⁶² ⁵	Klumpen HJ...Richel DJ	21189378	2011
25	Distant metastasis occurs late during the genetic evolution of pancreatic cancer. ⁶² ⁵⁷	Yachida S...Iacobuzio-Donahue CA	20981102	2010
26	The patterns and dynamics of genomic instability in metastatic pancreatic cancer. ⁶² ⁵⁷	Campbell PJ...Futreal PA	20981101	2010
27	Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). ⁶² ⁵	Carter H...Karchin R	20581473	2010
28	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. ⁶² ⁵⁷	Petersen GM...Chanock SJ	20101243	2010
29	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. ⁶² ⁵⁷	Amundadottir L...Hoover RN	19648918	2009
30	MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. ⁵³ ⁶² ⁴⁶	Ji Q...Xu L	19714243	2009
31	Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. ⁶² ⁵⁷	Olive KP...Tuveson DA	19460966	2009
32	Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. ⁵³ ⁶² ⁴⁶	Lee KH...Maitra A	19407485	2009
33	Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. ⁶² ⁵⁷	McWilliams RR...Petersen GM	15912495	2005
34	Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. ⁶² ⁵⁷	Thayer SP...Hebrok M	14520413	2003
35	Progression model for pancreatic cancer. ⁶² ⁵⁷	Hruban RH...Kern SE	10955772	2000
36	Inheritance of pancreatic cancer in pancreatic cancer-prone families. ⁶² ⁵⁷	Banke MG...Aston CE	10872424	2000
37	Characterization of a carboxy-terminal BRCA1 interacting protein. ⁶² ⁵	Wong AK...Bartel PL	9811458	1998
38	Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. ⁶² ⁵⁷	Lowenfels AB...Whitcomb DC	9091646	1997
39	Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. ⁶² ⁵⁷	Whelan AJ...Goodfellow PJ	7666917	1995
40	MTS-1 (CDKN2) tumor suppressor gene deletions are a frequent event in esophagus squamous cancer and pancreatic adenocarcinoma cell lines. ⁵³ ⁵⁷	Liu Q...Rustgi AK	7845688	1995
41	Medical genetic study of eight pancreatic cancer-prone families. ⁶² ⁵⁷	Lynch HT...Lynch JF	7874567	1995
42	Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. ⁶² ⁵	Motojima K...Kanematsu T	8439212	1993
43	Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. ⁶² ⁵⁷	Ehrenthal D...Compton C	3828965	1987
44	Pancreatic cancer in father and son. ⁶² ⁵⁷	Reimer RR...Bender R	67325	1977
45	Familial carcinoma of the pancreas. ⁶² ⁵⁷	Friedman JM...Fialkow PJ	1269168	1976
46	A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE). ⁶² ⁴¹	van Goor IWJM...Dutch Pancreatic Cancer Group	36307892	2022
47	The fungal mycobiome promotes pancreatic oncogenesis via activation of MBL. ⁵⁷	Aykut B...Miller G	31578522	2019
48	The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. ⁵⁷	Seifert L...Miller G	27049944	2016
49	The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. ⁵⁷	Liu C...Lu Y	24859531	2014
50	p53 status determines the role of autophagy in pancreatic tumour development. ⁵⁷	Rosenfeldt MT...Ryan KM	24305049	2013

Sources

Genes for Pancreatic Cancer

Genes related to Pancreatic Cancer (32 elite genes):

(show top 50) (show all 585)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	SMAD4	SMAD Family Member 4	Protein Coding	1117.31	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries Pathways & Interactions Functions (show sections)	8653691 25240578 16135802 (more) 10415855 9644295 11553622 14639103 16137582 18985820 9098646 12352188 11866987 9892110 11866919 12905795 14669329 15110786 10436786 14607700 18310088 10327057 10092624 12479060 9705534 9389648 19139111 17997817 11751510 9312063 9288786 9197522 12569386 15855639 10626800 15626919 10623651 15289325 15626916 19058223 15565642 10797267 10944227 11323508 11783110 15592526 17018631 18519681 15084978 15014009 12379307 9307274 16320109 11115575 11040453 10769633 18787631 14762439 14695784 8957088 16443684 19896100 19260747 18949401 17111879 19064568 16791201 11021814 10810347 10487520 15184872 19629168 11135319 10975709 10781087 10766191 10667205 8752209 15637742 10220513 19002021 17297654 16171565 12618756 8898652 17469085 16549325 19686287 19273710 10950061 9443985 9438601 9276865 19546161 11169959 11278805 9850059 19584151 12622415
2	TP53	Tumor Protein P53	Protein Coding	1093.29	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	8513440 25240578 11075991 (more) 15810085 12561067 9869513 10353750 20110284 17230496 10750666 8269631 16759529 19609950 8026879 10950039 10732293 10624116 9252715 8927612 16274047 12609076 18617777 16481301 15643503 16255879 8137263 7698709 12918127 16808798 11313791 1764370 15534911 9854494 9166944 14695784 11115575 11244980 18049799 9706132 20370686 16425381 11753042 11097231 9058294 11015084 10473098 9529487 8604235 14981919 11497278 10737712 7872670 7947633 20156675 17106238 11758254 10217065 12384795 9880774 9703910 8807362 9252195 7947080 1630814 19896100 18847491 16752411 16280307 12605716 14535878 12171884 11585734 11523052 10950061 17297654 16171565 14502645 14612290 10680837 10436811 10090408 9322121 7554069 20018721 10436809 10415873 10076772 9788535 9276865 7586509 18344687 10481119 10090407 9438602 18999925 18376314 17488476 16995472 15097860 9219065
3	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1081.7	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications Pathways & Interactions (show sections)	7773929 8439212 17332249 (more) 20805368 20949522 21079152 22499344 22683711 25240578 16257181 17203180 15236190 11751396 11668624 19028876 12189555 18075308 17611392 10873061 16382049 18699769 8893335 15150585 19460940 16757361 19424582 11358848 18413263 18022911 16549325 11291084 20232877 19208745 19002021 18776302 17353198 10950061 19023234 17111879 15782177 19064568 19533561 20208318 15251944 16367914
3	KRAS::MIR96 ⁴⁶	MIR96 Macro RNA (hsa-miR-96) targets KRAS
4	STK11	Serine/Threonine Kinase 11	Protein Coding	1055.36	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10362809 21189378 14511408 (more) 15516847 10436774
5	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	496.35	Pathogenic ⁵ Risk factor ⁵ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	7894492 8644703 10788334 (more) 8833256 18940477 18762988 18855126 19140568 19029836 15173085 15796958 18439109 12237281 9134530 15162061 12670518 10667595 14531499 16973716
6	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	482.76	Pathogenic ⁵ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications Summaries (show sections)	15145354 12569143 17301269 (more) 8968085 15112280 19140568 11196174 19433978 18437078 11950811 12622420 11075991 16243825 18855126 15173085 15806175 8840963 19896100 14726700 8673090 10436774 9438601 8640236 19070627 18264087 15162061 14531499 16973716 11888897 11207041 10667595 9438603 19690177 18818508 14981540 8988179 8950667 14966099 18787609 18657973 12120238 10793087 9560268 18674702 12670518 12120226 16417627 15796958 9134530
7	PALB2	Partner And Localizer Of BRCA2	Protein Coding	456.05	Pathogenic ⁵ Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications (show sections)	20412113 21365267
8	ATM	ATM Serine/Threonine Kinase	Protein Coding	451.55	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15097860 18381943
9	CHEK2	Checkpoint Kinase 2	Protein Coding	445.33	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
10	MIR21	MicroRNA 21	RNA Gene	432.06	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19435867 18642050
11	MIR17	MicroRNA 17	RNA Gene	429.6	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	20703102 16461460
12	MIR221	MicroRNA 221	RNA Gene	428.49	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19730150 16461460
13	C11orf65	Chromosome 11 Open Reading Frame 65	Protein Coding	425	Pathogenic ⁵ Likely pathogenic ⁵
14	MIR155	MicroRNA 155	RNA Gene	424.49	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	17911264 16966691
15	MIR10A	MicroRNA 10a	RNA Gene	421.66	Causal ⁴⁶ Unspecified ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	19747919 17473300
16	ACVR1B	Activin A Receptor Type 1B	Protein Coding	420.76	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11248065 9714055
17	RBBP8	RB Binding Protein 8, Endonuclease	Protein Coding	416.52	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	9811458
18	BRIP1	BRCA1 Interacting Helicase 1	Protein Coding	415.42	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
19	TSC1	TSC Complex Subunit 1	Protein Coding	415.31	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
20	NBN	Nibrin	Protein Coding	415.23	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
21	FANCE	FA Complementation Group E	Protein Coding	414.88	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
22	POLD1	DNA Polymerase Delta 1, Catalytic Subunit	Protein Coding	409.85	Pathogenic ⁵ DISEASES inferred ¹⁴ ¹⁴
23	TMEM71	Transmembrane Protein 71	Protein Coding	400	Pathogenic ⁵
24	RABL3	RAB, Member Of RAS Oncogene Family Like 3	Protein Coding	383.8	Causative germline mutation ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications Summaries (show sections)	31406347
25	MIR34A	MicroRNA 34a	RNA Gene	378.12	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	17540599
26	MIR483	MicroRNA 483	RNA Gene	376.12	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	21112326
27	MIR34C	MicroRNA 34c	RNA Gene	367.22	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴ ¹⁴	19714243
28	MIR15A	MicroRNA 15a	RNA Gene	365.28	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	21106054
29	MIR34B	MicroRNA 34b	RNA Gene	362.62	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴ ¹⁴	19714243
30	MIR96	MicroRNA 96	RNA Gene	362.08	Causal ⁴⁶ DISEASES inferred ¹⁴ ¹⁴	21112326
31	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	75.53	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Disorders Publications (show sections)	25240578 12898359 11110976 (more) 16258260 9389057 12895341 9242437 15148814 12000709 7726912 9815833 12910525 11075991 9863014 14584079 10688850 15860351 10037301 11706079 10937052 10210535 7880531 11815963 18813118 17696250 8640765 7640518 12352668 19140568 18541514 14506146 12479060 10627132 11490843 12454511 10861313 12935400 16759529 10632358 10956390 11283541 11313791 11832084 16481301 15146471 9735394 17505013 9841966 15832197 10719365 17198183 16905682 17106238 10996726 14604895 9438601 15336553 16893909 12903437 11115575 19478948 9364657 11113097 18674702 7845688 9219065 11687897 12605716 10950061 9538137 9276865 17111879 15662124 11753042 11741799 20099499 18024887 17035234 15979573 9438603 19690177 16127777 10660490 8950667 19194757 19020940 19002021 17659731 17047042 12459645 10630172 9058294 8589035 19751883 17992582 16397522 15985168 11792751 10436774 8613012 7666916 18299477 11169959 19896100 13679454
32	PALLD	Palladin, Cytoskeletal Associated Protein	Protein Coding	71.74	Susceptibility factor ⁵⁸ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Disorders Publications Summaries Expressions (show sections)	17194196
33	LINC00673	Long Intergenic Non-Protein Coding RNA 673	RNA Gene	167.45	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	27213290
34	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	163.77	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)	24920070
35	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	162.92	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	22614017 24667321 25912306 (more) 27028998 27895308 28476883
36	PVT1	Pvt1 Oncogene	RNA Gene	162.4	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	21316338 25668599 27028998 (more) 28355965 28657147
37	UCA1	Urothelial Cancer Associated 1	RNA Gene	162.02	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	21593646 27562722 28315290 (more) 29510195
38	HOTTIP	HOXA Distal Transcript Antisense RNA	RNA Gene	161.76	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	25889214 25912306 26447755 (more) 27546609 28947139
39	GAS5	Growth Arrest Specific 5	RNA Gene	161.47	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	24026436 29112934
40	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	161.21	Experimental evidence ³⁷ DISEASES inferred ¹⁴ ¹⁴	25910082
41	NEAT1	Nuclear Paraspeckle Assembly Transcript 1	RNA Gene	161.19	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	27888106
42	LINC-ROR	Long Intergenic Non-Protein Coding RNA, Regulator Of Reprogramming	RNA Gene	161.04	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴ ¹⁴	26636540 26898939 27785603 (more) 28580169
43	TUG1	Taurine Up-Regulated 1	Protein Coding	160.86	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴ ¹⁴	28617552
44	XIST	X Inactive Specific Transcript	RNA Gene	160.79	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	28295543 29393501
45	CDKN2B-AS1	CDKN2B Antisense RNA 1	RNA Gene	160.32	Experimental evidence: Interaction ³⁷ DISEASES inferred ¹⁴ ¹⁴	28344092
46	CCAT1	Colon Cancer Associated Transcript 1	RNA Gene	160.31	Experimental evidence: Expression ³⁷ DISEASES inferred ¹⁴ ¹⁴	28078015
47	CYTOR	Cytoskeleton Regulator RNA	RNA Gene	160.12	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	25910082
48	CASC2	Cancer Susceptibility 2	RNA Gene	160.07	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	28865121
49	CRNDE	Colorectal Neoplasia Differentially Expressed	RNA Gene	160.07	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴
50	LINC00261	Long Intergenic Non-Protein Coding RNA 261	RNA Gene	159.85	Experimental evidence: Regulation ³⁷ DISEASES inferred ¹⁴ ¹⁴	25910082

Sources

Variations for Pancreatic Cancer

ClinVar genetic disease variations for Pancreatic Cancer:

⁵ (show top 50) (show all 130)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RBBP8	NM_002894.3(RBBP8):c.1009A>G (p.Lys337Glu)	SNV	Pathogenic	5824	rs121434388	GRCh37: 18:20572799-20572799 GRCh38: 18:22992836-22992836
2	STK11	NM_000455.5(STK11):c.108C>A (p.Tyr36Ter)	SNV	Pathogenic	7452	rs137853079	GRCh37: 19:1207020-1207020 GRCh38: 19:1207021-1207021
3	STK11	NM_000455.5(STK11):c.650del (p.Pro217fs)	DEL	Pathogenic	7453	rs397518442	GRCh37: 19:1220629-1220629 GRCh38: 19:1220630-1220630
4	STK11	NM_000455.5(STK11):c.936del (p.Lys312fs)	DEL	Pathogenic	7454	rs397518443	GRCh37: 19:1222997-1222997 GRCh38: 19:1222998-1222998
5	SMAD4	NM_005359.6(SMAD4):c.1072G>T (p.Gly358Ter)	SNV	Pathogenic	8536	rs121912576	GRCh37: 18:48591909-48591909 GRCh38: 18:51065539-51065539
6	SMAD4	NM_005359.6(SMAD4):c.1477G>C (p.Asp493His)	SNV	Pathogenic	8538	rs121912578	GRCh37: 18:48604655-48604655 GRCh38: 18:51078285-51078285
7	SMAD4	NM_005359.6(SMAD4):c.1543A>T (p.Arg515Ter)	SNV	Pathogenic	8539	rs121912579	GRCh37: 18:48604721-48604721 GRCh38: 18:51078351-51078351
8	TP53	NM_000546.6(TP53):c.105G>T (p.Leu35Phe)	SNV	Pathogenic	12371	rs121912661	GRCh37: 17:7579582-7579582 GRCh38: 17:7676264-7676264
9	POLD1	NM_002691.4(POLD1):c.3148del (p.Arg1050fs)	DEL	Pathogenic	1077091		GRCh37: 19:50920456-50920456 GRCh38: 19:50417199-50417199
10	BRIP1	NM_032043.3(BRIP1):c.1328_1334del (p.Cys443fs)	DEL	Pathogenic	1077092		GRCh37: 17:59876467-59876473 GRCh38: 17:61799106-61799112
11	FANCE	NM_021922.3(FANCE):c.929dup (p.Val311fs)	DUP	Pathogenic	655390	rs587778337	GRCh37: 6:35425714-35425715 GRCh38: 6:35457937-35457938
12	ACVR1B	NM_004302.5(ACVR1B):c.1159_1163del (p.Asp387fs)	DEL	Pathogenic	8227	rs387906389	GRCh37: 12:52380624-52380628 GRCh38: 12:51986840-51986844
13	PALB2	NM_024675.4(PALB2):c.1652dup (p.Tyr551Ter)	DUP	Pathogenic	560017	rs1555461176	GRCh37: 16:23646214-23646215 GRCh38: 16:23634893-23634894
14	STK11	NM_000455.5(STK11):c.716G>A (p.Trp239Ter)	SNV	Pathogenic	931293	rs730881975	GRCh37: 19:1220698-1220698 GRCh38: 19:1220699-1220699
15	BRCA2	NM_000059.4(BRCA2):c.1989del (p.Phe663fs)	DEL	Pathogenic	254495	rs886038068	GRCh37: 13:32910478-32910478 GRCh38: 13:32336341-32336341
16	BRCA2	NM_000059.4(BRCA2):c.7415dup (p.Cys2473fs)	DUP	Pathogenic	1077094		GRCh37: 13:32929402-32929403 GRCh38: 13:32355265-32355266
17	ACVR1B	NM_004302.5(ACVR1B):c.1262-502_1392+24del	DEL	Pathogenic	8228	rs1555162597	GRCh37: 12:52385141-52385797 GRCh38: 12:51991357-51992013
18	SMAD4	NM_005359.6(SMAD4):c.1236C>G (p.Tyr412Ter)	SNV	Pathogenic	24845	rs121912577	GRCh37: 18:48593485-48593485 GRCh38: 18:51067115-51067115
19	KRAS	NM_004985.5(KRAS):c.35G>A (p.Gly12Asp)	SNV	Pathogenic	12582	rs121913529	GRCh37: 12:25398284-25398284 GRCh38: 12:25245350-25245350
20	KRAS	NM_004985.5(KRAS):c.35G>T (p.Gly12Val)	SNV	Pathogenic	12583	rs121913529	GRCh37: 12:25398284-25398284 GRCh38: 12:25245350-25245350
21	TP53	NM_000546.6(TP53):c.818G>A (p.Arg273His)	SNV	Pathogenic	12366	rs28934576	GRCh37: 17:7577120-7577120 GRCh38: 17:7673802-7673802
22	BRCA2	NM_000059.4(BRCA2):c.6405_6409del (p.Asn2135fs)	DEL	Pathogenic	38043	rs80359584	GRCh37: 13:32914894-32914898 GRCh38: 13:32340757-32340761
23	PALB2	NM_024675.4(PALB2):c.2167_2168del (p.Met723fs)	DEL	Pathogenic	136132	rs587776416	GRCh37: 16:23641307-23641308 GRCh38: 16:23629986-23629987
24	SMAD4	NM_005359.6(SMAD4):c.1082G>A (p.Arg361His)	SNV	Pathogenic	24832	rs377767347	GRCh37: 18:48591919-48591919 GRCh38: 18:51065549-51065549
25	SMAD4	NM_005359.6(SMAD4):c.1498A>G (p.Ile500Val)	SNV	Pathogenic	30150	rs281875322	GRCh37: 18:48604676-48604676 GRCh38: 18:51078306-51078306
26	KRAS	NM_004985.5(KRAS):c.458A>T (p.Asp153Val)	SNV	Pathogenic	12587	rs104894360	GRCh37: 12:25362838-25362838 GRCh38: 12:25209904-25209904
27	TP53	NM_000546.6(TP53):c.743G>A (p.Arg248Gln)	SNV	Pathogenic	12356	rs11540652	GRCh37: 17:7577538-7577538 GRCh38: 17:7674220-7674220
28	TP53	NM_000546.6(TP53):c.559+1G>A	SNV	Pathogenic	428908	rs1131691042	GRCh37: 17:7578370-7578370 GRCh38: 17:7675052-7675052
29	TP53	NM_000546.6(TP53):c.524G>A (p.Arg175His)	SNV	Pathogenic	12374	rs28934578	GRCh37: 17:7578406-7578406 GRCh38: 17:7675088-7675088
30	TP53	NM_000546.6(TP53):c.96+1G>T	SNV	Pathogenic	482212	rs1131691003	GRCh37: 17:7579699-7579699 GRCh38: 17:7676381-7676381
31	SMAD4	NM_005359.6(SMAD4):c.1245_1248del (p.Asp415Glufs)	DEL	Pathogenic	142253	rs80338965	GRCh37: 18:48593491-48593494 GRCh38: 18:51067121-51067124
32	BRCA2	NM_000059.4(BRCA2):c.4525C>T (p.Gln1509Ter)	SNV	Pathogenic	51659	rs80358683	GRCh37: 13:32913017-32913017 GRCh38: 13:32338880-32338880
33	BRCA2	NM_000059.4(BRCA2):c.6408_6414del (p.Asn2137fs)	DEL	Pathogenic	52086	rs397507851	GRCh37: 13:32914898-32914904 GRCh38: 13:32340761-32340767
34	ATM	NM_000051.4(ATM):c.2502dup (p.Val835fs)	DUP	Pathogenic	127351	rs587779822	GRCh37: 11:108137931-108137932 GRCh38: 11:108267204-108267205
35	ATM	NM_000051.4(ATM):c.3802del (p.Glu1267_Val1268insTer)	DEL	Pathogenic	127374	rs587779834	GRCh37: 11:108155008-108155008 GRCh38: 11:108284281-108284281
36	ATM	NM_000051.4(ATM):c.1A>G (p.Met1Val)	SNV	Pathogenic	181942	rs730881359	GRCh37: 11:108098352-108098352 GRCh38: 11:108227625-108227625
37	BRCA1	NM_007294.4(BRCA1):c.2411_2412del (p.Gln804fs)	DEL	Pathogenic	37466	rs80357664	GRCh37: 17:41245136-41245137 GRCh38: 17:43093119-43093120
38	BRCA1	NM_007294.4(BRCA1):c.2263G>T (p.Glu755Ter)	SNV	Pathogenic	54516	rs41286296	GRCh37: 17:41245285-41245285 GRCh38: 17:43093268-43093268
39	CHEK2	NM_007194.4(CHEK2):c.846+4_846+7del	DEL	Pathogenic	216652	rs764884641	GRCh37: 22:29105987-29105990 GRCh38: 22:28709999-28710002
40	CHEK2	NM_007194.4(CHEK2):c.908+1540_1095+330del	DEL	Pathogenic	1077093		GRCh37: 22:29092559-29097953 GRCh38: 22:28696571-28701965
41	BRCA2	NM_000059.4(BRCA2):c.475G>A (p.Val159Met)	SNV	Pathogenic	51711	rs80358702	GRCh37: 13:32900287-32900287 GRCh38: 13:32326150-32326150
42	BRCA2	NM_000059.4(BRCA2):c.1813dup (p.Ile605fs)	DUP	Pathogenic	37762	rs80359306	GRCh37: 13:32907428-32907428 GRCh38: 13:32333283-32333284
43	BRCA2	NM_000059.4(BRCA2):c.3545_3546del (p.Gln1181_Phe1182insTer)	DEL	Pathogenic	37846	rs80359388	GRCh37: 13:32912036-32912037 GRCh38: 13:32337899-32337900
44	BRCA2	NM_000059.4(BRCA2):c.5073dup (p.Trp1692fs)	DUP	Pathogenic	37943	rs80359479	GRCh37: 13:32913565-32913565 GRCh38: 13:32339421-32339422
45	BRCA2	NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter)	SNV	Pathogenic	38099	rs80358972	GRCh37: 13:32930609-32930609 GRCh38: 13:32356472-32356472
46	BRCA2	NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His)	SNV	Pathogenic	52515	rs41293511	GRCh37: 13:32937506-32937506 GRCh38: 13:32363369-32363369
47	BRCA2	NM_000059.4(BRCA2):c.8755-1G>A	SNV	Pathogenic	38183	rs81002812	GRCh37: 13:32953453-32953453 GRCh38: 13:32379316-32379316
48	BRCA1	NM_007294.4(BRCA1):c.3770_3771del (p.Glu1257fs)	MICROSAT	Pathogenic	37546	rs80357579	GRCh37: 17:41243777-41243778 GRCh38: 17:43091760-43091761
49	BRIP1	NM_032043.3(BRIP1):c.2684_2687del (p.Val894_Ser895insTer)	DEL	Pathogenic	241642	rs760551339	GRCh37: 17:59763415-59763418 GRCh38: 17:61686054-61686057
50	NBN	NM_002485.5(NBN):c.657_661del (p.Lys219fs)	DEL	Pathogenic	6940	rs587776650	GRCh37: 8:90983442-90983446 GRCh38: 8:89971214-89971218

Cosmic variations for Pancreatic Cancer:

⁸ (show top 50) (show all 630)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM90142044	TRAF7	pancreas,NS,carcinoma,acinar carcinoma	c.1187A>G	p.Q396R	16:2173972-2173972	32
2	COSM84313984	TRAF2	pancreas,NS,carcinoma,acinar carcinoma	c.876G>T	p.E292D	9:136920431-136920431	32
3	COSM120694978	SPOP	pancreas,NS,carcinoma,acinar carcinoma	c.838-1G>A	p.?	17:49602008-49602008	32
4	COSM121998482	SPOP	pancreas,NS,carcinoma,acinar carcinoma	c.838-1G>A	p.?	17:49602008-49602008	32
5	COSM100986702	SPOP	pancreas,NS,carcinoma,acinar carcinoma	c.838-1G>A	p.?	17:49602008-49602008	32
6	COSM92461094	SPOP	pancreas,NS,carcinoma,acinar carcinoma	c.838-1G>A	p.?	17:49602008-49602008	32
7	COSM151944134	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
8	COSM151626276	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
9	COSM131023131	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
10	COSM111397487	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
11	COSM89661338	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
12	COSM151570633	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
13	COSM109739345	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
14	COSM151424813	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
15	COSM151524008	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
16	COSM149468859	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
17	COSM150576869	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
18	COSM106820556	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
19	COSM148672905	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
20	COSM112784932	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
21	COSM140844884	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
22	COSM151249776	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
23	COSM148061297	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
24	COSM138940468	SMARCA4	pancreas,NS,carcinoma,acinar carcinoma	c.1369G>A	p.E457K	19:10991273-10991273	32
25	COSM103090674	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1156G>C	p.G386R	18:51067035-51067035	32
26	COSM139776915	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.868G>C	p.G290R	18:51067035-51067035	32
27	COSM91386650	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1600C>T	p.Q534*	18:51078408-51078408	32
28	COSM103083840	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1597C>A	p.L533I	18:51078405-51078405	32
29	COSM103089012	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1600C>T	p.Q534*	18:51078408-51078408	32
30	COSM139771981	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1309C>A	p.L437I	18:51078405-51078405	32
31	COSM91381131	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1597C>A	p.L533I	18:51078405-51078405	32
32	COSM139775765	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1312C>T	p.Q438*	18:51078408-51078408	32
33	COSM91388156	SMAD4	pancreas,NS,carcinoma,acinar carcinoma	c.1156G>C	p.G386R	18:51067035-51067035	32
34	COSM103029577	SETD2	pancreas,NS,carcinoma,acinar carcinoma	c.4325C>A	p.S1442*	3:47120311-47120311	32
35	COSM149744235	SETD2	pancreas,NS,carcinoma,acinar carcinoma	c.-26C>A	p.?	3:47120311-47120311	32
36	COSM137016084	RPTOR	pancreas,NS,carcinoma,acinar carcinoma	c.485G>A	p.G162E	17:80707977-80707977	32
37	COSM130781152	RPTOR	pancreas,NS,carcinoma,acinar carcinoma	c.485G>A	p.G162E	17:80707977-80707977	32
38	COSM88247526	RPTOR	pancreas,NS,carcinoma,acinar carcinoma	c.485G>A	p.G162E	17:80707977-80707977	32
39	COSM93826387	ROS1	pancreas,NS,carcinoma,acinar carcinoma	c.5738C>A	p.A1913D	6:117321280-117321280	32
40	COSM93857613	ROS1	pancreas,NS,carcinoma,acinar carcinoma	c.5756C>A	p.A1919D	6:117321280-117321280	32
41	COSM107060151	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.704T>A	p.I235N	17:40354489-40354489	32
42	COSM98725155	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.1043T>A	p.I348N	17:40354489-40354489	32
43	COSM98729090	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.995T>A	p.I332N	17:40354489-40354489	32
44	COSM107058842	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.994G>T	p.G332C	17:40356122-40356122	32
45	COSM86830145	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.995T>A	p.I332N	17:40354489-40354489	32
46	COSM98724291	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.1333G>T	p.G445C	17:40356122-40356122	32
47	COSM98728207	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.1285G>T	p.G429C	17:40356122-40356122	32
48	COSM86828778	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.1285G>T	p.G429C	17:40356122-40356122	32
49	COSM98707819	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.1270G>T	p.G424C	17:40356122-40356122	32
50	COSM98708620	RARA	pancreas,NS,carcinoma,acinar carcinoma	c.980T>A	p.I327N	17:40354489-40354489	32

Copy number variations for Pancreatic Cancer from CNVD:

⁶ (show top 50) (show all 15981)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13839	1	100027661	100101597	Gain and loss	AGL	Pancreatic cancer
2	13849	1	100147561	100201027	Gain and loss	SLC35A3	Pancreatic cancer
3	13857	1	100215810	100260948	Gain and loss	MFSD14A	Pancreatic cancer
4	13861	1	100261125	100310532	Gain and loss	SASS6	Pancreatic cancer
5	13862	1	10027309	10175557	Gain and loss	UBE4B	Pancreatic cancer
6	13871	1	100326522	100355822	Gain and loss	LRRC39	Pancreatic cancer
7	13875	1	100372897	100427397	Gain and loss	DBT	Pancreatic cancer
8	13880	1	100443784	100469348	Gain and loss	RTCA	Pancreatic cancer
9	13887	1	100530068	100697853	Gain and loss	CDC14A	Pancreatic cancer
10	13901	1	100715714	100719589	Gain and loss	GPR88	Pancreatic cancer
11	13916	1	100897318	100916618	Gain and loss	VCAM1	Pancreatic cancer
12	13924	1	101049969	101073575	Gain and loss	EXTL2	Pancreatic cancer
13	13925	1	101073653	101157013	Gain and loss	SLC30A7	Pancreatic cancer
14	13931	1	101167641	101203392	Gain and loss	DPH5	Pancreatic cancer
15	13942	1	101414596	101419094	Gain and loss	S1PR1	Pancreatic cancer
16	13966	1	101980154	102174569	Gain and loss	OLFM3	Pancreatic cancer
17	13979	1	10205097	10375920	Gain and loss	KIF1B	Pancreatic cancer
18	14027	1	103055016	103286073	Gain and loss	COL11A1	Pancreatic cancer
19	14059	1	103780424	103834168	Gain and loss	RNPC3	Pancreatic cancer
20	14081	1	103871529	103880389	Gain and loss	AMY2A	Pancreatic cancer
21	14091	1	103910910	103919188	Gain and loss	AMY1A	Pancreatic cancer
22	14093	1	10393351	10414467	Gain and loss	PGD	Pancreatic cancer
23	14151	1	10424425	10446476	Gain and loss	CENPS	Pancreatic cancer
24	14168	1	10454871	10466879	Gain and loss	DFFA	Pancreatic cancer
25	14176	1	10469278	10625079	Gain and loss	PEX14	Pancreatic cancer
26	14277	1	10641535	10790973	Gain and loss	CASZ1	Pancreatic cancer
27	14348	1	107311380	107313956	Gain and loss	PRMT6	Pancreatic cancer
28	14354	1	107395591	107665249	Gain and loss	NTNG1	Pancreatic cancer
29	14396	1	107825832	108219580	Gain and loss	VAV3	Pancreatic cancer
30	14412	1	107915304	108309068	Gain or loss	VAV3	Pancreas cancer
31	14435	1	108389491	108454940	Gain and loss	SLC25A24	Pancreatic cancer
32	14445	1	108477129	108498715	Gain and loss	NBPF4	Pancreatic cancer
33	14472	1	108630504	108640564	Gain and loss	NBPF5P	Pancreatic cancer
34	14486	1	108815093	108889808	Gain and loss	EEIG2	Pancreatic cancer
35	14495	1	108947005	108956462	Gain and loss	PRPF38B	Pancreatic cancer
36	14496	1	108977028	108997407	Gain and loss	FNDC7	Pancreatic cancer
37	14498	1	109001350	109064190	Gain and loss	STXBP3	Pancreatic cancer
38	14509	1	109131869	109185060	Gain and loss	GPSM2	Pancreatic cancer
39	14514	1	109184172	109218121	Gain and loss	CLCC1	Pancreatic cancer
40	14518	1	109224882	109296777	Gain and loss	WDR47	Pancreatic cancer
41	14530	1	109319187	109330611	Gain and loss	TAF13	Pancreatic cancer
42	14538	1	109368575	109461639	Gain and loss	ELAPOR1	Pancreatic cancer
43	14554	1	109468582	109492827	Gain and loss	SARS1	Pancreatic cancer
44	14558	1	109504683	109530414	Gain and loss	CELSR2	Pancreatic cancer
45	14588	1	109568465	109652615	Gain and loss	SORT1	Pancreatic cancer
46	14603	1	109594163	109619901	Gain or loss	CELSR2	Pancreas cancer
47	14615	1	109656520	109681079	Gain and loss	PSMA5	Pancreatic cancer
48	14617	1	109721142	109734212	Gain and loss	SYPL2	Pancreatic cancer
49	14619	1	109738603	109747396	Gain and loss	ATXN7L2	Pancreatic cancer
50	14623	1	109748763	109755097	Gain and loss	CYB561D1	Pancreatic cancer

Sources

Expression for Pancreatic Cancer

Search GEO for disease gene expression data for Pancreatic Cancer.

Sources

Pathways for Pancreatic Cancer

Pathways related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 50)

#	Super pathways	Score	Top Affiliating Genes
1	Gene expression (Transcription) ⁶⁶ Show member pathways Generic Transcription Pathway ⁶⁶ RNA Polymerase II Transcription ⁶⁶	14.06	TSC1 TP53 STK11 SMAD4 RBBP8 NBN
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.81	ATM BRCA1 CHEK2 KRAS NBN SMAD4
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.79	TP53 SMAD4 RBBP8 PALB2 NBN KRAS
4	Cell Cycle, Mitotic ⁶⁶ Show member pathways Cell Cycle ⁶⁶ M Phase ⁶⁶	13.5	TP53 RBBP8 NBN CHEK2 BRIP1 BRCA2
5	Homology Directed Repair ⁶⁶ Show member pathways Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex ⁶⁶ DNA Double-Strand Break Repair ⁶⁶ DNA Repair ⁶⁶ G2/M DNA damage checkpoint ⁶⁶ HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) ⁶⁶ HDR through MMEJ (alt-NHEJ) ⁶⁶ Processing of DNA double-strand break ends ⁶⁶	13.21	TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
6	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.94	ATM BRCA1 BRIP1 CHEK2 NBN RBBP8
7	TCR Signaling (Qiagen) ⁶⁴ Show member pathways Fc-EpsilonRI Pathway ⁶⁴ ITK and TCR Signaling ⁶⁴ PDGF Pathway ⁶⁴ PKC-Theta Pathway ⁶⁴	12.93	ATM BRCA1 BRCA2 BRIP1 CHEK2 KRAS
8	Cell Cycle Checkpoints ⁶⁶ Show member pathways G2/M Checkpoints ⁶⁶	12.81	ATM BRCA1 BRIP1 CHEK2 NBN RBBP8
9	Homologous DNA Pairing and Strand Exchange ⁶⁶ Show member pathways Defective Base Excision Repair Associated with NEIL1 ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA2 loss of function ⁶⁶ Diseases of Base Excision Repair ⁶⁶ Diseases of DNA Double-Strand Break Repair ⁶⁶ Diseases of DNA repair ⁶⁶ Fanconi anemia pathway ⁶¹ Fanconi Anemia Pathway ⁶⁶ HDR through Homologous Recombination (HRR) ⁶⁶ HDR through Single Strand Annealing (SSA) ⁶⁶ Impaired BRCA2 binding to RAD51 ⁶⁶ Presynaptic phase of homologous DNA pairing and strand exchange ⁶⁶	12.78	RBBP8 PALB2 NBN BRIP1 BRCA2 BRCA1
10	Meiosis ⁶⁶ Show member pathways Meiotic recombination ⁶⁶ Meiotic synapsis ⁶⁶ Reproduction ⁶⁶	12.71	RBBP8 NBN BRCA2 BRCA1 ATM
11	DNA repair pathways, full network ⁷⁴ Show member pathways Defective Mismatch Repair Associated With MSH2 ⁶⁶ Defective Mismatch Repair Associated With MSH3 ⁶⁶ Defective Mismatch Repair Associated With MSH6 ⁶⁶ Diseases of Mismatch Repair (MMR) ⁶⁶ Dual Incision in GG-NER ⁶⁶ Homologous recombination ⁷⁴ Mismatch Repair ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) ⁶⁶ Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) ⁶⁶ Non-homologous end joining ⁷⁴ Nucleotide excision repair ⁷⁴ Nucleotide excision repair in xeroderma pigmentosum ⁷⁴ Nucleotide Excision Repair Pathway ⁶⁴	12.66	PALB2 NBN BRIP1 BRCA2 BRCA1 ATM
12	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.64	TP53 NBN CHEK2 BRCA2 BRCA1 ATM
13	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.47	TP53 SMAD4 NBN KRAS BRCA2 BRCA1
14	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.46	TP53 KRAS CHEK2 ATM ACVR1B
15	DNA Double Strand Break Response ⁶⁶ Show member pathways Nonhomologous End-Joining (NHEJ) ⁶⁶ Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks ⁶⁶ Sensing of DNA Double Strand Breaks ⁶⁶	12.4	ATM BRCA1 CHEK2 NBN TP53
16	DNA Damage ³	12.39	ATM BRCA1 BRCA2 BRIP1 CHEK2 NBN
17	Resolution of D-loop Structures through Holliday Junction Intermediates ⁶⁶ Show member pathways Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function ⁶⁶ Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function ⁶⁶ Defective homologous recombination repair (HRR) due to BRCA1 loss of function ⁶⁶ Defective homologous recombination repair (HRR) due to PALB2 loss of function ⁶⁶ Impaired BRCA2 binding to PALB2 ⁶⁶ Resolution of D-Loop Structures ⁶⁶ Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) ⁶⁶	12.29	RBBP8 PALB2 NBN BRIP1 BRCA2 BRCA1
18	Cell cycle ⁷⁴ Show member pathways G1 to S cell cycle control ⁷⁴	12.24	TP53 SMAD4 CHEK2 ATM
19	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.2	TP53 CHEK2 BRCA1 ATM
20	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.16	TP53 NBN CHEK2 BRCA1 ATM
21	mTOR Signaling ⁶⁵	12.1	TSC1 TP53 STK11 KRAS
22	DNA damage response (only ATM dependent) ⁷⁴	11.95	TP53 SMAD4 KRAS ATM
23	ATM Pathway ⁶⁴ Show member pathways ATM signaling pathway ⁷⁴	11.85	TP53 NBN CHEK2 BRCA1 ATM
24	Head and neck squamous cell carcinoma ⁷⁴	11.79	TSC1 TP53 STK11 SMAD4 KRAS
25	DNA IR-double strand breaks and cellular response via ATM ⁷⁴ Show member pathways ATM pathway ⁶¹ DNA damage_DNA-damage-induced responses ²²	11.79	TP53 RBBP8 NBN CHEK2 BRCA2 BRCA1
26	Integrated breast cancer pathway ⁷⁴	11.79	TSC1 TP53 STK11 SMAD4 KRAS CHEK2
27	Validated targets of C-MYC transcriptional activation ⁶¹	11.78	TP53 SMAD4 NBN
28	mTOR Pathway ⁷⁰ Show member pathways TGF-beta Pathway ⁷⁰	11.77	TP53 KRAS ACVR1B
29	Cell differentiation - expanded index ⁷⁴ Show member pathways Cell differentiation - index ⁷⁴	11.77	MIR221 MIR17 MIR155
30	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.75	TP53 CHEK2 ATM
31	miRNAs involved in DNA damage response ⁷⁴	11.73	TP53 MIR221 MIR21 MIR17 ATM
32	E2F transcription factor network ⁶¹	11.69	RBBP8 BRCA1 ATM
33	Pathways affected in adenoid cystic carcinoma ⁷⁴	11.65	TP53 BRCA1 ATM
34	Hepatitis C and hepatocellular carcinoma ⁷⁴	11.65	TP53 SMAD4 MIR155 BRCA1
35	BRCA1 Pathway ⁶⁴ Show member pathways Fanconi's Anaemia Pathway ⁶⁴	11.62	TP53 RBBP8 NBN CHEK2 BRCA2 BRCA1
36	p53 pathway ⁶¹	11.55	TP53 CHEK2 ATM
37	ATM signaling in development and disease ⁷⁴	11.51	STK11 RBBP8 NBN CHEK2 ATM
38	Cell cycle Role of 14-3-3 proteins in cell cycle regulation ²² Show member pathways 14-3-3 and Cell Cycle Regulation ⁶⁴	11.5	ATM CHEK2 TP53
39	Integrated cancer pathway ⁷⁴	11.47	TP53 CHEK2 BRCA1 ATM
40	DNA damage_ATM/ATR regulation of G1/S checkpoint ²²	11.47	TP53 NBN CHEK2 BRCA1 ATM
41	LKB1 signaling events ⁶¹	11.45	TSC1 TP53 STK11 SMAD4
42	miRNA regulation of p53 pathway in prostate cancer ⁷⁴	11.34	TP53 CHEK2 ATM
43	GADD45 Pathway ⁶⁴	11.33	TP53 BRCA1 ATM
44	Transcription_Transcription factor Tubby signaling pathways ²²	11.3	TP53 KRAS ATM
45	BARD1 signaling events ⁶¹	11.23	TP53 RBBP8 NBN BRCA1 ATM
46	DNA IR-damage and cellular response via ATR ⁷⁴	11.18	TP53 RBBP8 PALB2 NBN CHEK2 BRIP1
47	DNA Damage Induced 14-3-3Sigma Signaling ⁶⁴	11.09	TP53 BRCA1 ATM
48	SMC1/SMC3 role in DNA damage - Cornelia de Lange Syndrome ⁷⁴	10.83	NBN BRCA1 ATM
49	DDX1 as a regulatory component of the Drosha microprocessor ⁷⁴	10.53	NBN ATM
50	PLK3 signaling events ⁶¹	10.52	TP53 CHEK2 ATM

Sources

GO Terms for Pancreatic Cancer

Cellular components related to Pancreatic Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	10.03	TSC1 TP53 STK11 SMAD4 PALB2 BRCA2
2	nuclear ubiquitin ligase complex	GO:0000152	9.62	BRCA2 BRCA1
3	BRCA1-B complex	GO:0070532	9.46	BRIP1 BRCA1
4	BRCA1-C complex	GO:0070533	9.43	RBBP8 NBN BRCA1
5	DNA repair complex	GO:1990391	9.23	PALB2 BRCA2 BRCA1 ATM

Biological processes related to Pancreatic Cancer according to GeneCards Suite gene sharing:

(show all 41)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of gene expression	GO:0010628	10.38	TP53 MIR21 MIR17 KRAS BRCA1 ATM
2	regulation of cell cycle	GO:0051726	10.33	ATM BRCA1 NBN STK11 TP53 TSC1
3	negative regulation of cell population proliferation	GO:0008285	10.31	TSC1 TP53 STK11 SMAD4 MIR221 MIR21
4	in utero embryonic development	GO:0001701	10.22	TP53 SMAD4 PALB2 NBN ACVR1B
5	negative regulation of cell growth	GO:0030308	10.19	ACVR1B BRCA1 SMAD4 STK11 TP53
6	negative regulation of gene expression	GO:0010629	10.18	TP53 MIR21 MIR17 MIR155 BRIP1 ACVR1B
7	somitogenesis	GO:0001756	10.16	TP53 PALB2 ATM
8	regulation of signal transduction by p53 class mediator	GO:1901796	10.15	STK11 CHEK2 ATM
9	nucleotide-excision repair	GO:0006289	10.14	TP53 BRIP1 BRCA2
10	response to ionizing radiation	GO:0010212	10.14	ATM BRCA1 STK11
11	cellular response to ionizing radiation	GO:0071479	10.13	TP53 BRCA2 BRCA1
12	cell population proliferation	GO:0008283	10.13	TSC1 TP53 SMAD4 NBN KRAS BRCA2
13	mitotic G2 DNA damage checkpoint signaling	GO:0007095	10.12	NBN BRCA1 ATM
14	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	10.1	BRCA2 CHEK2 TP53
15	mitotic G2/M transition checkpoint	GO:0044818	10.07	BRCA1 NBN RBBP8
16	DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	GO:0006977	10.06	TP53 CHEK2 ATM
17	DNA damage checkpoint signaling	GO:0000077	10.06	NBN CHEK2 BRIP1 ATM
18	DNA repair	GO:0006281	10.06	RBBP8 PALB2 NBN CHEK2 BRIP1 BRCA2
19	intrinsic apoptotic signaling pathway in response to DNA damage	GO:0008630	10.05	CHEK2 BRCA2 BRCA1 ATM
20	signal transduction in response to DNA damage	GO:0006975	10.04	CHEK2 ATM
21	signal transduction in response to DNA damage	GO:0042770	10.04	CHEK2 ATM
22	positive regulation of transforming growth factor beta receptor signaling pathway	GO:0030511	10.03	STK11 SMAD4 MIR21
23	replicative senescence	GO:0090399	10.03	TP53 CHEK2 ATM
24	double-strand break repair via homologous recombination	GO:0000724	10.03	RBBP8 PALB2 NBN BRCA2 BRCA1 ATM
25	response to gamma radiation	GO:0010332	10.02	TP53 CHEK2 BRCA2
26	cell cycle	GO:0007049	10.01	ATM BRCA1 BRCA2 CHEK2 NBN RBBP8
27	DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	GO:0006978	10	TP53 CHEK2 BRCA2
28	positive regulation of epithelial to mesenchymal transition	GO:0010718	9.98	SMAD4 MIR221 MIR21
29	positive regulation of cardiac muscle cell apoptotic process	GO:0010666	9.97	TP53 SMAD4 MIR17
30	negative regulation of telomere capping	GO:1904354	9.96	NBN ATM
31	female gonad development	GO:0008585	9.91	SMAD4 BRCA2 ATM
32	DNA strand resection involved in replication fork processing	GO:0110025	9.91	RBBP8 NBN BRCA1
33	cellular response to gamma radiation	GO:0071480	9.91	TP53 MIR21 CHEK2 ATM
34	positive regulation of vascular associated smooth muscle cell proliferation	GO:1904707	9.85	MIR221 MIR21 MIR17
35	chordate embryonic development	GO:0043009	9.85	BRCA2 BRCA1
36	cellular response to DNA damage stimulus	GO:0006974	9.83	TP53 STK11 RBBP8 PALB2 NBN CHEK2
37	homologous recombination	GO:0035825	9.76	BRCA1 BRIP1 NBN RBBP8
38	negative regulation of vascular associated smooth muscle cell apoptotic process	GO:1905460	9.66	MIR21 MIR17
39	positive regulation of metalloendopeptidase activity	GO:1904685	9.65	MIR21 MIR17
40	negative regulation of interleukin-21 production	GO:0032705	9.61	MIR221 MIR21
41	double-strand break repair	GO:0006302	9.47	TP53 NBN CHEK2 BRIP1 BRCA2 BRCA1

Molecular functions related to Pancreatic Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein N-terminus binding	GO:0047485	9.76	TSC1 TP53 NBN ATM
2	mRNA 3'-UTR binding	GO:0003730	9.43	TP53 MIR21 MIR17 MIR155 MIR10A
3	mRNA base-pairing translational repressor activity	GO:1903231	9.02	MIR221 MIR21 MIR17 MIR155 MIR10A